No price history available.

Based on consensus from external analysts. Not Kvantra's opinion.

Nanjing Vazyme Biotech Co., Ltd., a prominent biotechnology firm, specializes in the comprehensive investigation, development, and manufacturing of essential biological components. These core offerings include enzymes, antigens, antibodies, and unique polymer organic compounds. The company's extensive product portfolio encompasses a broad spectrum of scientific research reagents. This range features solutions for advanced techniques such as PCR cloning and point mutation, nucleic acid extraction, reverse transcription, quantitative PCR (qPCR), cell and protein analysis, gene editing applications, and user-friendly instant granule formulations. Furthermore, Vazyme provides sophisticated reagents crucial for high-throughput sequencing library construction, including those for DNA and RNA library preparation, single-cell epigenetics, magnetic bead-based methodologies, quantitative assays, and the effective storage and extraction of cell-free DNA. Complementing these, the company also delivers a variety of biomedical reagents and related services. Vazyme's diverse clientele spans scientific research institutions, specialized high-throughput sequencing service providers, manufacturers of molecular diagnostic reagents, pharmaceutical enterprises, contract research organizations (CROs), hospitals, and other healthcare facilities. Established in 2012, the company maintains its headquarters in Nanjing, China.

• Aktis Oncology, Inc.
• Novavax, Inc.
• Immatics N.V.
• Inhibrx Biosciences Inc.
• LB Pharmaceuticals Inc Common Stock
• MannKind Corporation
• HBM Holdings Limited
• Monte Rosa Therapeutics, Inc.